Efficacy and safety of vardenafil for kidney transplant recipients with erectile dysfunction.
- Author:
Jun YANG
1
,
2
;
Wen JU
;
Fu-qing ZENG
;
Ya-jun XIAO
;
Xiao-ping ZHANG
;
Chuan-guo XIAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Double-Blind Method; Erectile Dysfunction; drug therapy; etiology; Humans; Imidazoles; therapeutic use; Kidney Transplantation; Male; Middle Aged; Phosphodiesterase Inhibitors; therapeutic use; Piperazines; therapeutic use; Renal Dialysis; Sulfones; therapeutic use; Triazines; therapeutic use; Vardenafil Dihydrochloride
- From: National Journal of Andrology 2008;14(10):911-913
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of vardenafil in kidney transplant recipients with erectile dysfunction.
METHODSThirty-nine kidney transplant recipients with erectile dysfunction (ED) and serum creatinine values <2 mg/dl were enrolled in a 4-week randomized, double blind, placebo-controlled study, 19 treated with placebo and 20 with vardenafil. Vardenafil efficacy was assessed with the IIEF questionnaire after 4 weeks of treatment, and its safety appraised by measuring serum creatinine levels, creatinine clearances and cyclosporine concentrations before and after the treatment.
RESULTSIIEF scores improved from 12.6 +/- 3.4 to 26.5 +/- 2.8 (P < 0.01), but renal function and cyclosporine concentrations remained unchanged in the vardenafil-treated patients. Adverse effects were observed in 4 patients: headache in 2, palpitation and flush in 1, and dyspepsia in the other.
CONCLUSIONOral vardenafil therapy has a high efficacy and a low incidence of adverse events for kidney transplant recipients with ED.
